Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00542919 · ClinicalTrials.gov registry record · Phase 2
A Study for Patients With Non-Hodgkin's Lymphomas
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00542919 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 57 participants.
The verdict
NCT00542919, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
In this study, all patients will get investigational drug. There will be no comparator drug. This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and Aggressive B-cell lymphoma. Each tumor type will include several tumor subtypes: * T-cell lymphoma: Peripheral and Cutaneous T-cell lymphoma (PTCL, CTCL) * Indolent B-cell lymphoma: Small lymphocytic lymphoma, follicular lymphoma (Gr 1 or 2) and marginal zone lymphoma * Aggressive B-cell lymphoma: Primary CNS lymphoma, follicular lymphoma (Gr 3a and 3b) and aggressive lymphoma with prior clinical history of indolent lymphoma.
Interventions
- DRUG enzastaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2007-11 |
| Est. Completion | 2018-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00542919
The ClinicalTrials.gov registry entry for NCT00542919 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which enzastaurin is the first listed.
NCT00542919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00542919 about?
NCT00542919 is a clinical study titled "A Study for Patients With Non-Hodgkin's Lymphomas". In this study, all patients will get investigational drug. There will be no comparator drug. This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and Aggressive B-cell lymphoma. Each tumor type will include several tumor subtypes: * T-cell lymphoma: Peripheral and ...
What is the current status of trial NCT00542919?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2007-11. Estimated completion is 2018-02-27.
What interventions are being tested in trial NCT00542919?
The interventions under investigation include: enzastaurin (DRUG).
Who is sponsoring clinical trial NCT00542919?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.